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abnormal cell migration, proliferation, and
apoptosis of vascular smooth muscle cells by
activating the GLP-1 receptor, and inhibiting
ERK1/2 and PI3K/Akt signaling pathways
Lili Shi1†, Ye Ji2†, Xiaoyan Jiang1, Lihong Zhou1, Ying Xu1, Yanbo Li1, Wei Jiang1, Ping Meng1 and Xiaomin Liu1*Abstract
Background: As a new anti-diabetic medicine, Liraglutide (LIRA), one of GLP-1 analogues, has been found to have
an anti-atherosclerotic effect. Since vascular smooth muscle cells (VSMCs) play pivotal roles in the occurrence of
diabetic atherosclerosis, it is important to investigate the role of LIRA in reducing the harmful effects of high-glucose
(HG) treatment in cultured VSMCs, and identifying associated molecular mechanisms.
Methods: Primary rat VSMCs were exposed to low or high glucose-containing medium with or without LIRA. They
were challenged with HG in the presence of phosphatidylinositol 3-kinase (PI3K), extracellular signal-regulated kinase
(ERK)1/2, or glucagon-like peptide receptor (GLP-1R) inhibitors. Cell proliferation and viability was evaluated using a Cell
Counting Kit-8. Cell migration was determined by Transwell migration and scratch wound assays. Flow cytometry and
Western blotting were used to determine apoptosis and protein expression, respectively.
Results: Under the HG treatment, VSMCs exhibited increased migration, proliferation, and phosphorylation of protein
kinase B (Akt) and ERK1/2, along with reduced apoptosis (all p < 0.01 vs. control). These effects were significantly
attenuated with LIRA co-treatment (all p < 0.05 vs. HG alone). Inhibition of PI3K kinase and ERK1/2 similarly attenuated
the HG-induced effects (all p < 0.01 vs. HG alone). GLP-1R inhibitors effectively reversed the beneficial effects of LIRA on
HG treatment (all p < 0.05).
Conclusions: HG treatment may induce abnormal phenotypes in VSMCs via PI3K and ERK1/2 signaling pathways
activated by GLP-1R, and LIRA may protect cells from HG damage by acting on these same pathways.
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Cardiovascular disease remains the leading cause of
mortality and morbidity in diabetes mellitus (DM)
patients [1,2]. Atherosclerosis is a complication that can
be triggered by damage to vascular smooth muscle cells
(VSMCs) in DM patients [3]. High glucose (HG) levels
in the blood of DM patients often results in an enhanced* Correspondence: proflxm@outlook.com
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unless otherwise stated.generation of reactive oxygen species products, which
can stimulate the proliferation and migration of VSMCs,
causing accumulation of VSMCs in the intima of blood
vessels [4,5]. Additionally, abnormal apoptosis of VSMCs
has been observed in atherosclerosis and other DM-related
cardiovascular diseases [6]. In DM patients, HG inhibits
apoptosis of VSMCs by upregulating anti-apoptotic
proteins, including Bcl-2, Bcl-xL, and Bfl-1/A1 [7,8].
Overproliferation or reduced apoptosis of VSMCs
accelerates the deposition of atherosclerotic plaques in
the lining of blood vessels, and induces intimal thickening
and vascular remodeling [9]. Strategies preventings is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tion, and apoptosis may represent promising therapies for
protecting blood vessels against diabetic atherosclerosis.
Although the mechanisms by which HG influences
VSMC migration, proliferation, and apoptosis remain
unclear, in vitro studies indicate involvement of
phosphatidylinositol 3-kinase (PI3K)/protein kinase B
(Akt) and extracellular signal-regulated kinase (ERK)
pathways [10]. The ERK1/2 cascade functions in several
physiologic events, including cellular proliferation,
differentiation, and survival, and the serine/threonine
kinase Akt plays an essential role in cell proliferation,
migration, and protection against apoptosis [11,12]. In
animal studies, hyperglycemia can activate the ERK1/2
pathway in aortic VSMCs [13,14], and HG activates
ERK1/2 in cultured VSMCs, which could be an essential
event in mediating increased proliferation and migration,
and reduced apoptosis [13,15-19]. Hyperglycemia may
also inhibit apoptosis [16,20,21] and increase proliferation
of VSMCs via activating PI3K/Akt [22,23].
Glucagon-like peptide-1 (GLP-1), a gut incretin, modu-
lates glucose-dependent insulin secretion and suppresses
the release of glucagon [24]. A large body of evidence
indicates that GLP-1 plays an important role in the
pathogenesis of diabetic atherosclerosis. Long-term
treatment with GLP-1 effectively improves severe obesity,
hypertension, and lipid profiles, all of which are critical
risk factors in the development of atherosclerosis [25-28].
GLP-1 also has multiple therapeutic effects on the cardio-
vascular system, improving cardiac function and exerting
direct protective effects on cardiomyocytes [29-31], endo-
thelial cells [32,33], macrophages [34-36], and VSMCs [37].
Moreover, animal studies have demonstrated that GLP-1
can significantly inhibit atherosclerotic plaque deposition in
arteries, the formation of macrophage-derived foam cells
and the adhesion of mononuclear cells in the intima, and
attenuate the abnormal expression of CD36 [34,38]. It also
prevents vascular remodeling and protects endothelial cells
against oxidative stress via ameliorating intima inflamma-
tory reactions [24,39,40].
Although the molecular mechanisms responsible for the
effects of GLP-1 in the cardiovascular system are still un-
certain, anti-apoptotic effects of GLP-1 on cardiomyocytes
involve regulation of the PI3K/Akt and ERK1/2 signaling
pathways [31,41-43]. Furthermore, GLP-1 affects human
endothelial cell proliferation through phosphorylation of
Akt [44]. As these PI3K/Akt and ERK1/2 signaling path-
ways are also involved in the effects of HG on VSMCs
[13-15,19,20,22,23], we hypothesized that they are respon-
sible for the effects of GLP-1 on VSMCs treated with HG.
GLP-1 specifically binds to GLP-1 receptor (GLP-1R)
to stimulate the adenylyl cyclase pathway resulting in
increased insulin synthesis and release [45,46]. GLP-1R
is expressed on VSMCs [47], and platelet-derived growthfactor-induced VSMC cell proliferation is significantly inhi-
bited by a GLP-1R agonist (Exendin-4) [48]. However, no
efforts have been made to examine the direct effects of
GLP-1 on the HG-induced cell migration, proliferation,
and apoptosis of cultured VSMCs.
In this study, we investigated the role of liraglutide
(LIRA), a GLP-1 analog, in the attenuation of HG-induced
VSMC migration, proliferation, and reduced apoptosis.




Male Sprague Dawley rats (n = 4; 5–8 wks) were provided
by the Laboratory Animal Center of Harbin Medical
University, China. All procedures were performed in
accordance with guidelines set by the Institutional Animal
Care and Use Committee of the First Affiliated Hospital of
Harbin Medical University, which is in compliance with
the ARRIVE guidelines on animal research [49].
Reagents
LIRA was purchased from Novo Nordisk (Bagsvaerd,
Denmark). The ERK1/2 inhibitor (PD98059), PI3K inhibitor
(LY294002), and FITC-conjugated anti-α-smooth muscle
actin (α-SMA) monoclonal antibody were obtained
from Sigma-Aldrich (St Louis, MO, USA). The GLP-1R
antagonist, Exendin (9–39) (Exe(9–39)), was purchased
from AnaSpec (San Jose, CA, USA). Trypsin, fetal bovine
serum (FBS), and Dulbecco’s modified Eagle’s medium
(DMEM) were purchased from Gibco (of Thermo Fisher
Scientific, Waltham, MA, USA). Rabbit polyclonal anti-
bodies against ERK1/2, Akt and phosphorylated (p)-Akt,
and the mouse monoclonal antibody against p-ERK1/2 were
purchased from Santa Cruz Biotechnology Inc. (Dallas, TX,
USA). Rabbit polyclonal antibodies against β-actin, Bax,
Bcl-2, and caspase-3 were purchased from Abcam
(Cambridge, UK). Secondary antibodies were purchased
from Vector Labs (Burlingame, CA, USA). Western blot
bands were detected using the ECL Advance Western
blotting detection kit from GE Healthcare (Chalfont St
Giles, UK). Cell Counting Kit-8 was purchased from
Dojindo Molecular Technologies (Rockville, MD, USA).
Transwell plates were purchased from Millipore (Bedford,
MA, USA). Annexin V-FITC Kit was purchased from BD
Biosciences (San Jose, CA, USA).
Cell culture
VSMCs were prepared from thoracic aorta of Sprague
Dawley rats as previously described, with minor modifi-
cations [50]. Each rat was sacrificed and the whole thor-
acic aorta was isolated and washed several times in
phosphate buffered saline (PBS). After the adventitia and
intima were carefully removed, the aortic tissue was cut
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into a tissue culture flask and cultured in DMEM sup-
plemented with 15% FBS and maintained in a humidified
incubator at 37°C and 5% CO2. The cells were passaged
by trypsinization and reseeded into new flasks approxi-
mately 4–8 times before use in subsequent experiments.
VSMCs were identified by α-SMA staining.
Drug/chemical treatment
All cultures were incubated with serum-free media for
24 h prior to treatment. Cultures of VSMCs were
divided into the following groups: control (5 mM glucose);
HG (25 mM glucose); LIRA (100 nM; previously described
dose [51]); HG + LIRA (25 mM glucose and 100 nM
LIRA); osmotic (MG; 25 mM mannitol); HG + LY294002
(25 mM glucose and 50 μM LY294002 [52]); HG + LIRA +
LY294002 (25 mM glucose, 100 nM LIRA, and 50 μM
LY294002); HG+ PD98059 (25 mM glucose and 50 μM
PD98059 [53]); HG+ LIRA + PD98059 (25 mM glucose,
100 nM LIRA, and 50 μM PD98059); and HG+ LIRA +
Exe(9–39) (25 mM glucose, 100 nM LIRA, and 200 nM
Exe(9–39) [54,55]). All VSMCs cultures were pretreated
with the indicated drugs 1 h prior to HG treatment with
exception of Exe(9–39) treatment, which was added
30 min prior to HG treatment.
Cell proliferation assay
Cells were plated in 96-well culture plates and incubated
until reaching 80% confluency; the culture media was then
replaced with serum-free DMEM and incubated for an
additional 24 h. Cells were then treated with the media
containing the indicated concentration of various purposely
designed chemical(s) for an additional 48 h. Cell prolifera-
tion was then assessed using a Cell Counting Kit-8, follow-
ing the manufacturer’s instructions. Briefly, the colorimetric
reagent, 2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-
(2,4-disulfophenyl)-2H-tetrazolium monosodium salt,
was added to each sample and incubated for 1 h at 37°C.
Proliferation was then assessed by measuring absorbance
of each sample at the wavelength of 450 nm.
Transwell migration assay
Cell migration was determined using the Transwell
migration assay as previous described, with minor
modification [56]. Briefly, VSMCs were treated with
the indicated chemical(s) for 12 h at 37°C. The cells
were washed three times with PBS after the culture
media was removed and then trypsinized with 0.25%
(v/v) trypsin and resuspended in serum-free DMEM
at 37°C. These cells were then counted and the upper
chamber of each Transwell was seeded with 1 × 105
cells per chamber in 0.2 mL serum-free DMEM. As a
chemoattractant, 0.8 mL of DMEM supplemented with
20% FBS was added to the lower chamber of eachTranswell. Chambers were incubated for 12 h at 37°C with
5% CO2. Cells that migrated to the underside of the
Transwell filter were fixed with 4% formaldehyde (w/v)
for 20 min at room temperature and then immersed
into a hematoxylin staining solution for 15 min. After
washing with distilled water, membranes were mounted
on glass slides and examined by microscopy at 200×
magnification.
In vitro scratch wound assay
The migration capacity of VSMCs was also characterized
using a well-established in vitro scratch wound model,
with minor modifications [57]. VSMCs were grown to
confluence and then subjected to scratching using a
200 μL sterile pipette tip. The scratch wound was
allowed to heal for 24 h in the presence of the indicated
chemical(s). Micrographs were captured for each sample
at 0 and 24 h, and the capacity of VSMC migration was
evaluated by measuring the width of the scratch wound
at both time points using ImageJ [58].
Assessment of cell apoptosis
Cell apoptosis was measured using the Annexin V-FITC
kit, following the manufacturer’s instructions. Briefly,
cells treated with the indicated chemical(s) for 48 h and
then harvested by trypsinization. Cells were washed
twice by centrifugation and re-suspended in PBS. Cells
were then collected and re-suspended in 500 μL of the
binding buffer. These cells were then stained with 5 μL
of Annexin V-FITC and 5 μL of the propidium iodide
staining solution for 15 min at room temperature in the
dark. The percentage of Annexin V-FITC- and propidium
iodide-positive cells was measured by flow cytometry
(FACSAria, BD Biosciences, San Jose, USA).
Western blot analysis
All cells were collected and lysed in 200 μL radioimmu-
noprecipitation assay buffer with the protease inhibitor
phenylmethylsulfonyl fluoride (100 mM) for 1 h on ice.
Subsequently, the lysate was centrifuged at 12,000 × g for
5 min at 4°C. The supernatant was collected and the
total protein concentration was determined using a
bicinchoninic acid kit (Thermo Fisher Scientific). Ten μg
of total protein from each sample was separated by
electrophoresis using 12% SDS-PAGE gels and transferred
onto nitrocellulose membranes. The target proteins were
measured using the primary antibodies (1:10,000) and
their corresponding secondary antibodies (1:50,000),
followed by development with an ECL Advance Western
blotting detection kit. β-actin was detected as a loading
control. Signals were developed on X-ray films following
exposure to ECL advance luminescence. The intensity
of each band was quantified using Quantity One 4.62
(Bio-Rad Laboratories, Inc., Hercules, CA, USA). Levels of
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total protein: p-Akt relative to Akt and p-ERK1/2 relative
to ERK1/2.
Statistical analysis
All results were from three independent experiments
and are expressed as mean ± standard deviation. Data
were analyzed by one-way analysis of variance using SPSS
version 17.0 (SPSS Inc., Chicago, IL, USA). A p < 0.05 was
regarded as statistically significant.
Results
Characterization of VSMCs
The isolated VSMCs were identified by α-SMA staining,
a VSMC-specific marker. All cultures had comparable
numbers of cells and more than 98% of the cells were
α-SMA-positive (Figure 1).
LIRA inhibited HG-induced proliferation of VSMCs
VSMCs treated for 48 h with HG showed a significant
increase in cellular proliferation compared to controls
(1.99 ± 0.13 vs. 1.25 ± 0.15; p < 0.01), and pretreatment
with LIRA significantly attenuated this HG-induced VSMC
proliferation (1.62 ± 0.15; p < 0.01 vs. HG) (Figure 2).
Treatment of VSMCs with LIRA alone had no effect onA
DC
B
Figure 1 Identification of vascular smooth muscle cells (VSMCs) in pri
(B) Nuclear staining with DAPI (fluorescence) (C) α-smooth muscle actin st
nuclei and α-smooth muscle actin (fluorescence/immunofluorescence). Allcell proliferation, as compared to the control cells. To
exclude the possible influence of osmatic change on
VSMCs during the HG treatment, mannitol was used in
place of glucose, which had no effect on the proliferation
of VSMCs.LIRA inhibited HG-induced migration of VSMCs
The migration capacity of VSMCs was measured via
Transwell migration and in vitro scratch assays.
A significantly greater number of cells migrated through
the Transwell membrane in the HG group than in the
control group (86.40 ± 4.22 vs. 51.40 ± 2.30 cells; p < 0.01).
Treatment with LIRA or mannitol alone resulted in
no significant increase in migration, as compared to
the control group. LIRA pretreatment significantly
reduced the number of VSMCs that migrated following
HG treatment (72.40 ± 2.07 cells; p < 0.01 vs. HG)
(Figure 3A,B).
The scratch wound assay showed that treatment
with HG resulted in significantly more wound healing
than the control group (85.61 ± 6.36 vs. 37.25 ± 4.78%;
p < 0.01). LIRA pretreatment was able to attenuate
the effects of HG on VSMC migration (67.03 ± 5.61%;
p < 0.05 vs. HG) (Figure 3C,D). Treatment with LIRAmary cultures. (A) Primary cultures of VSMCs (phase contrast).
aining, a marker of VSMCs (immunofluorescence). (D) Co-staining of















Figure 2 Liraglutide (LIRA) inhibited high glucose (HG)-induced
proliferation in cultured vascular smooth muscle cells. Cell
proliferation was determined using Cell Counting Kit-8. All results are
presented as mean ± standard deviation from three independent
experiments; *p < 0.01 vs. control; #p < 0.01 vs. HG. MG =mannitol,








Figure 3 Liraglutide (LIRA) inhibited high glucose (HG)-induced migra
(A) Transwell filters were stained with hematoxylin to visualize migrated ce
Transwell migration assay; *p < 0.01 vs. control; #p < 0.01 vs. HG. (C) Conflue
24 h after wounding. The wound gaps in each culture were measured to ind
area in the scratch assays; *p < 0.01 vs. control; #p < 0.05 vs. HG. The results are
experiments. MG=mannitol, osmotic control.
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compared to the control group.LIRA attenuated the inhibitory effect of HG on VSMC
apoptosis
Treatment with HG for 48 h significantly reduced the num-
ber of apoptotic VSMCs compared to controls (1.34 ± 0.12
vs. 8.67 ± 0.87%; p < 0.01). Pretreatment of VSMCs with
LIRA in HG conditions resulted in a higher rate of
apoptosis (3.44 ± 0.89%; p < 0.05 vs. HG) (Figure 4A,B).
Treatment with LIRA or mannitol alone resulted in similar
numbers of apoptotic cells to the control sample.
To further investigate the mechanism of the HG-induced
reduction in apoptosis, the expression of relevant
apoptotic proteins was investigated by Western blotting
(Figure 4C,D). The anti-apoptotic protein Bcl-2 was
significantly upregulated (p < 0.01 vs. control) and the
pro-apoptotic proteins cleaved caspase-3 and BAX
were significantly downregulated after HG treatment
(p < 0.01 vs. control). LIRA pretreatment reduced those
effects by HG treatment, resulting in increased cleaved
caspase-3 and Bax levels, and decreased Bcl-2 levels
(p < 0.01 vs. HG) (Figure 4C,D). PD98059, LY294002
or Exe(9–39) alone had no effect on cleaved caspase-3
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Figure 4 (See legend on next page.)
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Figure 4 Liraglutide (LIRA) attenuated the inhibitory effects of high glucose (HG) on apoptosis of cultured vascular smooth muscle cells
(VSMCs). (A) Apoptosis was determined by staining with Annexin V-FITC (x-axis) and propidium iodide (y-axis). For each dot plot, the upper and lower
right quadrants represent early apoptotic and late apoptotic cells, respectively. (B) Quantification of the apoptosis experiments. Total apoptosis refers
to the sum of early and late apoptosis values. Results are expressed as mean ± standard deviation from three independent experiments; *p < 0.01 vs.
control; #p < 0.05 vs. HG. (C) Protein expression of cleaved caspase-3 in VSMCs; *p < 0.01 vs. control; #p < 0.01 vs. HG; †p < 0.05, **p < 0.01 vs. HG + LIRA.
(D) Protein expression of Bcl-2 and Bax in VSMCs; *p < 0.01, **p < 0.01 vs. control; #p < 0.01, ##p < 0.01 vs. HG. Protein expression was normalized to
β-actin. The results from three independent experiments are presented as mean ± standard deviation.
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VSMCs
Western blotting analysis showed that HG treatment
significantly increased the levels of p-Akt and p-ERK1/2
(both p < 0.01 vs. control). LY294002, PD98059, and Exe
(9–39) had no effect on either p-Akt or p-ERK1/2
expression (all p > 0.05 vs. control). LIRA plus either
LY294002 or PD98059 had no effect on p-Akt or p-ERK1/2
expression (all p > 0.05 vs. control) (Figure 5A,B).
LY294002 and PD98059 prevented the HG-induced
abnormal VSMC behaviors and the reduction of cell
apoptosis
Pretreatment with LY294002 or PD98059 reduced VSMC
proliferation following HG stimulation (1.57 ± 0.14 and
1.58 ± 0.14, respectively, vs. 1.99 ± 0.13; both p < 0.01)
(Figure 6A), Transwell migration (70.20 ± 3.11 and
70.60 ± 3.16, respectively, vs. 86.40 ± 4.22 cells; both p < 0.01)
(Figure 6B), and wound healing (64.55 ± 6.06 and
63.96 ± 7.71, respectively, vs. 85.61 ± 6.36%; both p < 0.05)
(Figure 6C). LY294002 and PD98059 were also effective in
increasing the rate of VSMC apoptosis (3.46 ± 0.31 and
3.93 ± 0.49, respectively, vs. 1.34 ± 0.12%; both p < 0.01 vs.
HG) (Figure 6D). Treatment of VSMCs with either
LY294002 or PD98059 under HG conditions also resulted
in increased protein levels of the cleaved caspase-3
(p < 0.01 vs. HG) (Figure 4C), and decreased p-Akt
and p-ERK1/2 (both p < 0.01 vs. HG) (Figure 5A,B).
LIRA exerted beneficial effects on the cultured VSMCs
with HG treatment via inhibiting PI3K/Akt and ERK1/2
signaling pathways
Pretreatment with LIRA effectively reduced the HG-
induced protein elevation of p-ERK1/2 and p-Akt (both
p < 0.01 vs. HG) (Figure 5A,B). Furthermore, compared to
LIRA alone, co-administration of LIRA with LY294002 or
PD98059 on VSMCs under HG synergistically reduced
cell proliferation (1.48 ± 0.14 and 1.41 ± 0.13, respectively,
vs. 1.62 ± 0.15; both p < 0.05) (Figure 7A) and migration in
the Transwell (61.60 ± 5.41 and 61.80 ± 4.09, respectively,
vs. 72.40 ± 2.07 cells; both p < 0.01) (Figure 7B) and wound
healing (46.28 ± 4.24 and 46.02 ± 7.34, respectively, vs.
67.03 ± 5.61%; both p < 0.05) (Figure 7C) assays, and
increased apoptosis (6.81 ± 0.28 and 6.15 ± 0.37, respectively,
vs. 3.44 ± 0.89%; both p < 0.01) (Figure 7D). Furthermore,co-administration of LIRA with LY294002 or PD98059 on
HG-treated VSMCs resulted in reduced p-Akt and p-ERK1/
2 levels (both p < 0.01 vs. HG+ LIRA) (Figure 5A,B).
Exe(9–39) abolished the beneficial effects of LIRA on
HG-treated VSMCs
Application of the GLP-1R antagonist Exe(9–39) amelio-
rated the effect of LIRA on VSMCs under HG treatment,
including a increased cell proliferation (1.94 ± 0.17 vs.
1.62 ± 0.15; p < 0.05) (Figure 7A) and migration detected
by the Transwell (86.2 ± 4.6 vs. 72.4 ± 2.07 cells; p < 0.01)
(Figure 7B) and wound healing (80.79 ± 7.99 vs. 63.07 ±
5.61%; p < 0.05) (Figure 7C) assays. Moreover, Exe(9–39)
reduced apoptosis (1.54 ± 0.29 vs. 3.44 ± 0.89%; p < 0.05)
(Figure 7D) and cleaved caspase-3 (p < 0.01) (Figure 4C)
in HG+ LIRA-treated cells. Finally, inhibition of GLP-1R
increased phosphorylation of ERK1/2 and Akt in HG+
LIRA-treated cells (both p < 0.05) (Figure 5).
Discussion
Atherosclerosis is the most common cardiovascular com-
plication of diabetes. Vascular remodeling is an important
component in the development of atherosclerosis, and both
are closely associated with pathologic changes in VSMCs,
including changes in proliferation, migration, and
apoptosis [59-61]. Previous studies have suggested
that HG concentrations promote these altered cellular
behaviors in VSMCs [15,16,22,62-64]. However, these
data are inconclusive and a mechanistic understanding is
still lacking.
The involvement of PI3K/Akt and ERK1/2 signaling
pathways in the HG-induced alteration of VSMC
migration, proliferation, and apoptosis
Previous studies have shown that the ERK1/2 signaling
pathway plays an important role in VSMC proliferation
[65], and insulin [66,67] or HG [13,14] could facilitate
proliferation via activation of this pathway. HG can also
induce dynamic changes in VSMCs through activation
of the PI3K/Akt pathway [16,20-23]. Therefore, these
pathways likely play a crucial role in the tissue damage
induced by hypertension and atherosclerosis.
To explore whether these signaling pathways are
involved in the HG-induced altered physiology of VSMCs,






























































































































































































































Figure 5 Liraglutide (LIRA) suppressed the high glucose (HG)-induced activation of PI3K/Akt and ERK1/2 signaling pathways by
activating the GLP-1 receptor. (A) Protein expression of phosphorylated Akt in vascular smooth muscle cells (VSMCs). (B) Protein expression of
phosphorylated ERK1/2 in VSMCs. Data from three independent experiments are expressed as mean ± standard deviation; *p < 0.01 vs. control;
#p < 0.01 vs. HG; **p < 0.05, †p < 0.01 vs. HG + LIRA.
Shi et al. Cardiovascular Diabetology  (2015) 14:18 Page 8 of 13ERK1/2 and PI3K/Akt activation. We then used specific
inhibitors to block these signaling pathways. We show, in
agreement with previous studies [13,15,17,23], thatHG treatment of VSMCs significantly increases the
phosphorylation of ERK1/2 and Akt. Furthermore, in-










































































































Figure 6 High glucose (HG) increased vascular smooth muscle cell (VSMC) migration and proliferation, and decreased cell apoptosis
in cultures via activation of the PI3K/Akt and ERK1/2 signaling pathways. (A) VSMC proliferation was determined using Cell Counting Kit-8.
(B) Representative photomicrographs showing migration of VSMCs in the Transwell migration assay (200× magnification). The relative amounts
of migrating cells in all groups are presented. (C) Representative photomicrographs showing the migrating cells in the scratch wound assay.
(D) Apoptosis rates were determined by flow cytometry, with the lower right and upper right quadrants representing early apoptotic and late
apoptotic cells, respectively. These values were quantified, and the total apoptotic rate is the sum of the early and late apoptotic rates. Data
from three independent experiments are expressed as mean ± standard deviation; *p < 0.01 vs. control; #p < 0.01 vs. HG. OD = optical density.
Shi et al. Cardiovascular Diabetology  (2015) 14:18 Page 9 of 13proliferation and migration. Pretreatment with ERK1/2 or
PI3K inhibitors also effectively prevents the ability of HG
to reduce VSMC apoptosis.Thus, our data demonstrate that HG treatment of
VSMCs alters cell migration, proliferation, and apoptosis















































































































Figure 7 Liraglutide (LIRA) exerted beneficial effects on cultured vascular smooth muscle cell (VSMCs) by activating the GLP-1 receptor
and inhibiting PI3K/Akt and ERK1/2 signaling pathways. (A) Cell proliferation of VSMCs; *p < 0.01 vs. control; #p < 0.01 vs. HG; †p < 0.05 vs.
HG + LIRA. (B) Representative photomicrographs showing migration of VSMCs in the Transwell migration assay (200× magnification). The relative
amounts of migrating cells in all groups are presented; *p < 0.01 vs. control; #p < 0.01 vs. HG; †p < 0.01 vs. HG + LIRA. (C) Representative photomicrographs
show the migrating cells in the scratch wound assay; *p < 0.01 vs. control; #p< 0.01 vs. HG; †p< 0.05 vs. HG + LIRA. (D) Apoptosis rates were determined
by flow cytometry, with the lower right and upper right quadrants representing early apoptotic and late apoptotic cells, respectively. These values were
quantified, and the total apoptotic rate is the sum of the early and late apoptotic rates; *p < 0.01 vs. control; #p< 0.05 vs. HG; †p< 0.01, **p < 0.05 vs.
HG + LIRA. Data from three independent experiments are expressed as mean ± standard deviation.
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underlying mechanism by which HG regulates VSMC
cell migration in diabetic patients. Furthermore, our
study identifies new research areas that may prove critical
in deciphering the pathogenesis of, and provides a novel
means to prevent, atherosclerosis in DM.
LIRA attenuates HG-induced cellular dynamic changes of
VSMCs by activating GLP-1R and inhibiting PI3K/Akt and
ERK1/2 signaling pathways
GLP-1 analogues and receptor agonists have been used in
the treatment of DM, increasing pancreatic protein
content and mass via boosting S6 kinase phosphorylation
and acinar cell mass [68]. LIRA, a GLP-1 analogue, effect-
ively lowers the body weight of diabetic patients, whichwas associated with enhancing plasma cardiac natriuretic
peptides levels [69]. Long-acting GLP-1 mimetics, such as
domain antibodies to serum albumin, can sustain the
activation of GLP-1R and reduce myocardial infarct size
and injury in acute coronary syndrome [70]. Another
GLP-1 agonist, exenatide, increases hydrogen sulfide,
carbon monoxide, and nitric oxide production, and then
reduces central arterial pressure in an animal model [71].
In carotid endarterectomy of diabetic patients, preopera-
tional use of GLP-1R agonists significantly increases the
expression of sirtuin-6, a protein involved in the inflamma-
tory pathway of diabetic atherosclerotic lesions and plaque
stabilization [72]. A prospective pilot clinical trial has
demonstrated that LIRA decreases carotid intima-media
thickness in patients with type 2 diabetes [73].
Shi et al. Cardiovascular Diabetology  (2015) 14:18 Page 11 of 13In this study, we show that HG-induced VSMC
alterations are prevented by treatment with LIRA. It
is possible that in DM patients, LIRA protects the
vascular system against atherosclerotic changes by
similar mechanisms. Our results also demonstrate that
LIRA by itself does not induce measurable physiologic
changes in VSMCs, but only blocks HG-induced effects.
Previous studies have shown that GLP-1 protects
cardiomyocytes and endothelial cells against cell apoptosis
by activating ERK1/2 and/or PI3K/Akt [31,44,74]. However,
our data demonstrate that LIRA inhibits this activation,
observed as reduced phosphorylation levels in VSMCs.
Moreover, synergistic effects are observed when LIRA
pretreatment is combined with ERK1/2 or PI3K inhibitors.
Although GLP-1 shows protections on cardiomyocytes and
endothelial cells by activating ERK1/2 and/or PI3K/Akt
[31,44,74], our data suggest that LIRA exerts the beneficial
effects on VSMCs in part via inhibiting ERK1/2 and PI3K/
Akt pathways. As VSMCs play a distinct role in the devel-
opment of diabetic atherosclerosis, the involvement of these
signaling pathways may be cell-type specific, which requires
further investigation.
Cardiomyocytes, endothelial cells, macrophages, and
VSMCs all express the GLP-1R, which mediates the
anti-inflammatory and anti-proliferation effects of GLP-1
[31,40,48]. To confirm that the effects of LIRA in
HG-treated cells occur via GLP-1R activation, VSMCs were
pretreated with Exe(9–39). Indeed, Exe(9–39) treatment
abolished the beneficial effects of LIRA treatment, and
reversed the suppression of Akt and ERK1/2 activation.
Conclusions
Collectively, this study shows that HG treatment facilitates
migration and proliferation of VSMCs, inhibits cell apop-
tosis, and increases the phosphorylation of ERK1/2 and
Akt. These effects are attenuated by LIRA pretreatment;
LIRA treatment reduced HG-induced phosphorylation of
ERK1/2 and Akt, suppressed cell migration and prolifera-
tion, and increased cell apoptosis. Moreover, inhibitors of
ERK1/2 and PI3K prevent the damaging effects of HG on
cultured VSMCs, suggesting that HG exerts injurious
effects via these signaling pathways. Importantly, we
also demonstrate that a GLP-1R antagonist can block
the beneficial effects of LIRA on VSMCs exposed to
HG. These effects were further enhanced by the co-
administration of inhibitors of ERK1/2 or PI3K, demon-
strating for the first time that LIRA treatment acts
through GLP-1R to regulate these signaling pathways. As
LIRA is an effective and safe therapeutic candidate, it may
become a promising treatment option in the prevention of
diabetic atherosclerosis.
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